Anti-CTLA-4 and anti-PD1/PDL1 therapy can be used to treat recurrent or refractory classical Hodgkin lymphoma, metastatic melanoma, and other tumors by mobilizing the function of the autoimmune system and fighting against cancer cells [54, 55], bringing hope to patients with advanced tumors. The gene discussed is CD274; the disease is cancer.